Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15927345 | 0.85 | ALDH1A1 (0.34) | GABRA1GABRB2SLC40A1ALDH1A1L3MBTL1 | |
| SCHEMBL17679294 | 0.85 | ALDH1A1 (0.34) | GABRA1GABRB2SLC40A1ALDH1A1L3MBTL1 | |
| SCHEMBL31085176 | 0.80 | PDE2A (0.39) | GABRA1GABRB2ALDH1A1L3MBTL1 | |
| SCHEMBL23489771 | 0.80 | PDE2A (0.39) | GABRA1GABRB2ALDH1A1L3MBTL1 | |
| SCHEMBL13713003 | 0.71 | GABRA1 (0.41) | GABRA1GABRB2SLC40A1ALDH1A1L3MBTL1 | |
| SCHEMBL15927758 | 0.71 | P2RX7 (0.39) | GABRA1GABRB2SLC40A1L3MBTL1HIF1A | |
| SCHEMBL24113945 | 0.71 | P2RX7 (0.39) | GABRA1GABRB2SLC40A1L3MBTL1HIF1A | |
| SCHEMBL23489779 | 0.71 | P2RX7 (0.39) | GABRA1GABRB2SLC40A1L3MBTL1HIF1A | |
| SCHEMBL5698980 | 0.71 | P2RX7 (0.39) | GABRA1GABRB2SLC40A1L3MBTL1HIF1A | |
| SCHEMBL24866880 | 0.69 | CA2 (0.37) | GABRA1GABRB2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | GABRA1 3965/4885GABRB2 3979/4885SLC40A1 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.